Interference with Tissue Factor Prolongs Intrahepatic Islet Allograft Survival in a Nonhuman Primate Marginal Mass Model
Authors:
- Dora M. BermanDBDora M. Berman
- Over CabreraOCOver Cabrera
- Norman M. KenyonNKNorman M. Kenyon
- Joshua MillerJMJoshua Miller
- Susan H. TamSTSusan H. Tam
- Vrinda S. KhandekarVKVrinda S. Khandekar
- Kristen M. PichaKPKristen M. Picha
- Avery R. SodermanASAvery R. Soderman
- Robert E. JordanRJRobert E. Jordan
- Peter J. BugelskiPBPeter J. Bugelski
- Denison HorningerDHDenison Horninger
- Michael LarkMLMichael Lark
- 15 August 2007
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 84 (3) , 308-315
Abstract
Tissue factor (TF) expression on islets can result in an instant blood-mediated inflammatory reaction (IBMIR) that contributes to early islet loss. We tested whether peritransplant protection of islets from IBMIR with a monoclonal anti-TF antibody (CNTO859) would enhance engraftment in our nonhuman primate marginal mass model. Each of six pairs of cynomolgus monkeys (CM) with streptozotocin-induced diabetes was closely matched for metabolic control and was transplanted with 5,000 IEQ/kg allogeneic, ABO-compatible islets from the same donor under the cover of steroid-free immunosuppression. For each pair, experimental animals received islets cultured with 20 μg/mL anti-TF and were dosed with 6 mg/kg anti-TF intravenously, 10–25 min before islet infusion; control monkeys received an equal number of islets from the same preparation cultured without anti-TF and no in vivo treatment. Early fasting C-peptide (CP) values were different between (P<0.01), but not within, pairs and correlated with in vitro functional capacity of islets as assessed by perifusion (r=0.60; P=0.022). Compared to their matched controls, experimental animals had decreased posttransplant markers of coagulation, higher fasting CP levels (1 month posttransplant and end of study) and prolonged graft function. These data suggest that pretreatment of islets and the recipient with anti-TF may limit the effects of IBMIR, thereby enhancing islet engraftment and survival.Keywords
This publication has 35 references indexed in Scilit:
- Islet Transplantation in Type 1 Diabetes Mellitus Using Cultured Islets and Steroid‐Free Immunosuppression: Miami ExperienceAmerican Journal of Transplantation, 2005
- Edmonton's islet success has indeed been replicated elsewhereThe Lancet, 2003
- Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantationThe Lancet, 2002
- Inhibition of Thrombin Abrogates the Instant Blood-Mediated Inflammatory Reaction Triggered by Isolated Human IsletsDiabetes, 2002
- β-Cell Death and Mass in Syngeneically Transplanted Islets Exposed to Short- and Long-Term HyperglycemiaDiabetes, 2002
- Clinical Outcomes and Insulin Secretion After Islet Transplantation With the Edmonton ProtocolDiabetes, 2001
- The Pleiotropic Effects of Tissue Factor: a Possible Role for Factor VIIa-induced Intracellular Signalling?Thrombosis and Haemostasis, 2001
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenNew England Journal of Medicine, 2000
- Blood coagulationThe Lancet, 2000
- Structural design and molecular evolution of a cytokine receptor superfamily.Proceedings of the National Academy of Sciences, 1990